Fan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fan Yang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Jinhui Wu
Pediatric Department, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
1 shared publicationLianlian Yang
Department of Child Health, West China Second University Hospital, Sichuan University, Chengdu City, China
1 shared publication- Lianlian Yang
Department of Child Health West China Second University Hospital Sichuan University Chengdu China
1 shared publication Mei Tang
Pediatric Department, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
1 shared publicationYini Wang
Pediatric Department, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
1 shared publicationYun Xiang
Pediatric Department, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
1 shared publication
Latest Publications
- Open Access
- 24 February 2025
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 31, e946284
Etiological Patterns of Protein-Energy Malnutrition in a Pediatric Clinic in China
BACKGROUND Protein-energy malnutrition (PEM) often occurs within 5 years of age. Untreated PEM in early childhood can affect growth and cognitive function later in life. However, the etiologies of PEM in children are still poorly explored. This study investigated the etiological distribution of PEM in children attending a pediatric health clinic. MATERIAL AND METHODS The study involved 286 children with PEM who visited the West China Second University Hospital Child Healthcare for Xinchuan West China Center for Child Development and Excellence from January to December 2022. Patients were divided into moderate and mild PEM groups according to the severity of PEM. A retrospective analysis of the etiology of PEM was conducted. RESULTS The top 5 etiologies of PEM were food allergy (FA) (57.0%), small for gestational age (SGA) (26.6%), dietary behavior problems (14.3%), premature infants (8.0%), and recurrent respiratory tract infections (RRTI) (4.5%). The proportions of SGA and RRTI patients in the moderate PEM group were significantly greater than the mild PEM group (P<0.001). The proportion of patients with 2 or more etiologies in the moderate PEM group was significantly greater than the mild PEM group (P<0.001). CONCLUSIONS The primary reasons for PEM in the investigated children were FA and SGA. Moderate PEM cases were mostly attributed to multiple etiologies. A multidisciplinary management approach involving pediatricians, nutritionists, and social workers is essential for addressing the complex needs of affected children. The importance of early diagnosis and timely management should be emphasized to reduce the number of PEM cases.
- 24 February 2025
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 31, e946284
Open AccessEtiological Patterns of Protein-Energy Malnutrition in a Pediatric Clinic in China
BACKGROUND Protein-energy malnutrition (PEM) often occurs within 5 years of age. Untreated PEM in early childhood can affect growth and cognitive function later in life. However, the etiologies of PEM in children are still poorly explored. This study investigated the etiological distribution of PEM in children attending a pediatric health clinic. MATERIAL AND METHODS The study involved 286 children with PEM who visited the West China Second University Hospital Child Healthcare for Xinchuan West China Center for Child Development and Excellence from January to December 2022. Patients were divided into moderate and mild PEM groups according to the severity of PEM. A retrospective analysis of the etiology of PEM was conducted. RESULTS The top 5 etiologies of PEM were food allergy (FA) (57.0%), small for gestational age (SGA) (26.6%), dietary behavior problems (14.3%), premature infants (8.0%), and recurrent respiratory tract infections (RRTI) (4.5%). The proportions of SGA and RRTI patients in the moderate PEM group were significantly greater than the mild PEM group (P<0.001). The proportion of patients with 2 or more etiologies in the moderate PEM group was significantly greater than the mild PEM group (P<0.001). CONCLUSIONS The primary reasons for PEM in the investigated children were FA and SGA. Moderate PEM cases were mostly attributed to multiple etiologies. A multidisciplinary management approach involving pediatricians, nutritionists, and social workers is essential for addressing the complex needs of affected children. The importance of early diagnosis and timely management should be emphasized to reduce the number of PEM cases.
- Open Access
- 13 January 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-8
Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis
To explore the effect of short-acting growth hormone (GH) supplementation on bone age and growth rate of children with idiopathic short stature. The authoritative databases such as PubMed, Medline, and Web of Science were extensively searched through the systematic and comprehensive literature retrieval strategy to compile the clinical research data on the treatment of idiopathic short stature with short-acting GH. The study will be strictly screened to ensure that all enrolled research subjects are patients with idiopathic short stature, and the intervention method is defined as short-acting GH replacement therapy, and a reasonable control group is set, such as placebo treatment, to ensure the scientificity and comparability of research results. Outcome index data such as basic characteristics, sample size, follow-up time, and total effective rate of the included studies were extracted. In this study, RevMan 5.3, a professional statistical software tool, was used to systematically perform the meta-analysis process. Weighted average difference (WMD) was calculated as the primary outcome to evaluate the effect of bone age and growth rate, and the WAD in adverse reactions was considered as the secondary outcome. Nine studies were included in the study, and 491 patients with idiopathic short stature were included in the study. The results of the meta-analysis showed that there was no significant difference in bone age but a significant difference in growth rate when compared with the control group. Short-acting GH supplementation can significantly improve the growth rate of children with idiopathic short stature, but has little effect on bone age.
- 13 January 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-8
Open AccessShort-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis
To explore the effect of short-acting growth hormone (GH) supplementation on bone age and growth rate of children with idiopathic short stature. The authoritative databases such as PubMed, Medline, and Web of Science were extensively searched through the systematic and comprehensive literature retrieval strategy to compile the clinical research data on the treatment of idiopathic short stature with short-acting GH. The study will be strictly screened to ensure that all enrolled research subjects are patients with idiopathic short stature, and the intervention method is defined as short-acting GH replacement therapy, and a reasonable control group is set, such as placebo treatment, to ensure the scientificity and comparability of research results. Outcome index data such as basic characteristics, sample size, follow-up time, and total effective rate of the included studies were extracted. In this study, RevMan 5.3, a professional statistical software tool, was used to systematically perform the meta-analysis process. Weighted average difference (WMD) was calculated as the primary outcome to evaluate the effect of bone age and growth rate, and the WAD in adverse reactions was considered as the secondary outcome. Nine studies were included in the study, and 491 patients with idiopathic short stature were included in the study. The results of the meta-analysis showed that there was no significant difference in bone age but a significant difference in growth rate when compared with the control group. Short-acting GH supplementation can significantly improve the growth rate of children with idiopathic short stature, but has little effect on bone age.
- Open Access
- 14 September 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (11)
A de novo heterozygous variant in the SON gene is associated with Zhu‐Tokita‐Takenouchi‐Kim syndrome
Background: Zhu‐Tokita‐Takenouchi‐Kim (ZTTK, OMIM# 617140) syndrome is a rare, autosomal dominant genetic disorder caused by heterozygous variants in the SON gene (OMIM#182465, GenBank#NC_000021.9). There are only 33 cases and 26 causative SON variants reported to date since the first report in 2015. Here, we report a new case of ZTTK syndrome and a de novo disease‐causing SON variant.Methods: We conducted whole‐exome sequencing (WES) to obtain genetic data of the patient. The clinical and genetic data of the patient were analyzed.Results: The clinical features of our patient were strikingly similar to previously reported cases. Notably, our patient had unique presentations, including a bridged palmar crease in the left hand and growth hormone deficiency. The c.5297del de novo variant in SON causes an amino change (p.Ser1766Leufs*7).Conclusion: Our report expands the mutant spectrum of the SON gene and refines the genotype‐phenotype map of ZTTK syndrome. Our findings also highlighted the importance of WES for early diagnosis of ZTTK syndrome, which may improve diagnostic procedures for affected individuals.
- 14 September 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (11)
Open AccessA de novo heterozygous variant in the SON gene is associated with Zhu‐Tokita‐Takenouchi‐Kim syndrome
Background: Zhu‐Tokita‐Takenouchi‐Kim (ZTTK, OMIM# 617140) syndrome is a rare, autosomal dominant genetic disorder caused by heterozygous variants in the SON gene (OMIM#182465, GenBank#NC_000021.9). There are only 33 cases and 26 causative SON variants reported to date since the first report in 2015. Here, we report a new case of ZTTK syndrome and a de novo disease‐causing SON variant.Methods: We conducted whole‐exome sequencing (WES) to obtain genetic data of the patient. The clinical and genetic data of the patient were analyzed.Results: The clinical features of our patient were strikingly similar to previously reported cases. Notably, our patient had unique presentations, including a bridged palmar crease in the left hand and growth hormone deficiency. The c.5297del de novo variant in SON causes an amino change (p.Ser1766Leufs*7).Conclusion: Our report expands the mutant spectrum of the SON gene and refines the genotype‐phenotype map of ZTTK syndrome. Our findings also highlighted the importance of WES for early diagnosis of ZTTK syndrome, which may improve diagnostic procedures for affected individuals.